In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster Session 2: Chronic Heart Failure – Treatment
Session

Event : Heart Failure 2019

Topic : Other

  • Session type : Poster Session
  • Date : 26 May 2019
  • Time : 08:30 - 18:00

50 presentations in this session

Benefits of full yogic breathing for patients with chronic heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : A Shevelyok (Donetsk,UA)

Analysis of the effectiveness of health education imparted by nursing in an heart failure unit

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : MDC Duran Torralba (Andujar,ES)

Utility of the implementation of a standardized evaluation program for therapeutic adherence in heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : MDC Duran Torralba (Andujar,ES)

A propensity-matched study of moderate to severe obesity and mortality in heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : PH Chu (Taipei,TW)

The influence of socio-clinical variables on the level of self-care in heart failure patients

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : M Wleklik (Wroclaw,PL)

Effects of time perspective and executive function on self-care in patients with heart failure: a cross-sectional study

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : HSJ Chew (Hong Kong,HK)

Real world usage and outcomes of all HFrEF patients treated with sacubitril/valsartan in Belgium

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : T Sente (Vilvoorde,BE)

Sacubitril-valsartan and its effect on ventricular remodeling

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : S Del Prado Diaz (Madrid,ES)

Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intake

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : H Morillas Climent (Valencia,ES)

Angiotensin receptor-neprilysin inhibition improves peak oxygen consumption in reduced heart failure patients

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : C Ferreira (Coimbra,PT)

Use of sacubitril-valsartan in elderly patients. Subanalysis of the SAVE-RLife study

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : M Galvan Ruiz (Las Palmas De G. C.,ES)

Allopurinol safety and efficacy in heart failure patients: a systematic review

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : MM Ansari Ramandi (Tehran,IR)

The impact of the use of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : A Almaghraby (Alexandria,EG)

The efficacy of "Get With the Guidelines Heart Failure," a retrospective analysis

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : P Fisher (Astoria,US)

Adherence to therapy in patients with chronic heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : E Efremova (Ulyanovsk,RU)

Quality of heart failure treatment treated by residential cardiologists -The HeartFailureBavaria Project

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : F Bisenius (Essen,DE)

The optimize-heart failure care program in our heart institute in Vietnam

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : T Do (Ho Chi Minh,VN)

Management of patients with advanced heart failure and type 2 pulmonary hypertension.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : M Hegarova (Praha 4,CZ)

Neuroendocrine inhibition in patients with heart failure and severe aortic stenosis undergoing TAVI

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : J Pino Moreno (Atlantis,US)

Levosemindan using in pediatric patients with end-stage heart failure: single center experience.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : A Baigalkanova (Astana,KZ)

Availability and accessibility to heart failure treatment in latin america

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : S Galindo (Cali,CO)

Decongestion therapy: does it differ from discharge to usual life conditions and among heart failure patients?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : F Adragao (Cascais,PT)

The European Heart Failure self-care behaviour scale: psychometric testing of the Hebrew version

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : T Ben Gal (Ramat Hasharon,IL)

Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : A Ntalianis (Athens,GR)

Prescription of sacubitril/valsartan in a real-world population

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : J AGOSTINHO (Lisboa,PT)

Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experience

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : F Ferreira (Cascais- Estoril,PT)

Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : V V Gomez Leiva (Ciudad De Mexico,MX)

The efficacy of nicorandil for patients with ischemic chronic heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : F Batar (Sibiu,RO)

Sequential nephron blockade with diuretics improves diastolic dysfunction in patients with resistant hypertension

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : D Fouassier (Paris,FR)

Optimising heart failure treatment following cardiac resynchronisation therapy

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : K Pryds (Aarhus N,DK)

Trimetazidine management: an extraordinary clinical response in patients with heart failure (TRIMEX-Study)

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : EJJ Chuquiure (Mexico City,MX)

Early left ventricular reverse remodeling after sacubitril-valsartan treatment. Subanalysis of SAVE-RLife study

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : M Galvan Ruiz (Las Palmas De G. C.,ES)

Impacts of mineralocorticoid receptor antagonists on mortality in heart failure patients with beta-blockers

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : NP Kato (Norrkoping,SE)

Response rate to sacubitril-valsartan in the community. Is there a clear phenotype?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : RB Pharithi (Dublin 16,IE)

Effects of sacubitril/valsartan on cardiac performance and exercise capacity

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : M Mapelli (Milano,IT)

Self-motivation, self-regulation and self-care in patients with heart failure: a sequential mixed-method study

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : HSJ Chew (Hong Kong,HK)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are